High-throughput screening and sensitized bacteria identify an M. tuberculosis dihydrofolate reductase inhibitor with whole cell activity

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Kumar, Anuradha ^a   Zhang, Meng ^b   Zhu, Linyun ^b   Liao, Reiling P ^a   Mutai, Charles ^b,c   Hafsat, Shittu ^b,d   Sherman, David R ^a   Wang, Ming Wei ^b  

^a SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^d NATIONAL INSTITUTE FOR PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; DIHYDROFOLATE REDUCTASE INHIBITOR; QUINAZOLINE;

ARTICLE; BACTERIAL STRAIN; CELL ACTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; EPIDEMIC; HIGH THROUGHPUT SCREENING; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIVITY ANALYSIS; TUBERCULOSIS; WHOLE CELL;

DIHYDROLIPOAMIDE DEHYDROGENASE; ENZYME INHIBITORS; FLUORESCENCE; HIGH-THROUGHPUT SCREENING ASSAYS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MYCOBACTERIUM TUBERCULOSIS; REPRODUCIBILITY OF RESULTS; TETRAHYDROFOLATE DEHYDROGENASE;

BACTERIA (MICROORGANISMS); MYCOBACTERIUM TUBERCULOSIS;

EID: 84863088810     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039961     Document Type: Article

References (25)

1. Nerlich AG, Haas CJ, Zink A, Szeimies U, Hagedorn HG, (1997) Molecular evidence for tuberculosis in an ancient Egyptian mummy. Lancet 350: 1404.
2. (2011) Global tuberculosis control report 2011. Geneva: WHO.
3. (2010) Treatment of tuberculosis: guidelines. WHO.
4. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, et al. (2009) Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran. Chest 136: 420-425.
5. (2011) 2011 TB Alliance Annual Report: Crossing Thresholds. New York: TB Alliance.
6. Kompis IM, Islam K, Then RL, (2005) DNA and RNA synthesis: antifolates. Chem Rev 105: 593-620.
7. Hitchings GH, Smith SL, (1980) Dihydrofolate reductases as targets for inhibitors. Adv Enzyme Regul 18: 349-371.
8. Bushby SR, Hitchings GH, (1968) Trimethoprim, a sulphonamide potentiator. Br J Pharmacol Chemother 33: 72-90.
9. Li R, Sirawaraporn R, Chitnumsub P, Sirawaraporn W, Wooden J, et al. (2000) Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J Mol Biol 295: 307-323.
10. Gerum AB, Ulmer JE, Jacobus DP, Jensen NP, Sherman DR, et al. (2002) Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase. Antimicrob Agents Chemother 46: 3362-3369.
11. El-Hamamsy MH, Smith AW, Thompson AS, Threadgill MD, (2007) Structure-based design, synthesis and preliminary evaluation of selective inhibitors of dihydrofolate reductase from Mycobacterium tuberculosis. Bioorg Med Chem 15: 4552-4576.
12. Argyrou A, Vetting MW, Aladegbami B, Blanchard JS, (2006) Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid. Nat Struct Mol Biol 13: 408-413.
13. Wang F, Jain P, Gulten G, Liu Z, Feng Y, et al. (2010) Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid. Antimicrob Agents Chemother 54: 3776-3782.
14. White EL, Ross LJ, Cunningham A, Escuyer V, (2004) Cloning, expression, and characterization of Mycobacterium tuberculosis dihydrofolate reductase. FEMS Microbiol Lett 232: 101-105.
15. Ehrt S, Guo XV, Hickey CM, Ryou M, Monteleone M, et al. (2005) Controlling gene expression in mycobacteria with anhydrotetracycline and Tet repressor. Nucleic Acids Res 33: e21.
16. Rustad TR, Harrell MI, Liao R, Sherman DR, (2008) The enduring hypoxic response of Mycobacterium tuberculosis. PLoS One 3: e1502.
17. Kutyavin IV, Afonina IA, Mills A, Gorn VV, Lukhtanov EA, et al. (2000) 3′-minor groove binder-DNA probes increase sequence specificity at PCR extension temperatures. Nucleic Acids Res 28: 655-661.
18. Zhang JH, Chung TD, Oldenburg KR, (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73.
19. Wang J, Soisson SM, Young K, Shoop W, Kodali S, et al. (2006) Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 441: 358-361.
20. Wei JR, Krishnamoorthy V, Murphy K, Kim JH, Schnappinger D, et al. (2011) Depletion of antibiotic targets has widely varying effects on growth. Proceedings of the National Academy of Sciences of the United States of America 108: 4176-4181.
21. Vilcheze C, Jacobs WR Jr, (2007) The mechanism of isoniazid killing: clarity through the scope of genetics. Annual review of microbiology 61: 35-50.
22. Gangjee A, Adair O, Queener SF, (2001) Synthesis of 2,4-diamino-6-(thioarylmethyl)pyrido[2,3-d]pyrimidines as dihydrofolate reductase inhibitors. Bioorg Med Chem 9: 2929-2935.
23. Hawser S, Lociuro S, Islam K, (2006) Dihydrofolate reductase inhibitors as antibacterial agents. Biochemical pharmacology 71: 941-948.
24. Dhople AM, (2002) In vivo activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with dapsone, against Mycobacterium leprae. Int J Antimicrob Agents 19: 71-74.
25. Rosowsky A, Hynes JB, Queener SF, (1995) Structure-activity and structure-selectivity studies on diaminoquinazolines and other inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. Antimicrob Agents Chemother 39: 79-86.